Category Archives: Best Stocks

Europe doesn’t like Trump administration’s tax plans

Europe’s five biggest economies have warned the Trump administration that its tax plan may violate international trade rules.

Germany, France, Britain, Spain and Italy have written to Treasury Sec. Steven Mnuchin, arguing that tax bills passed by the House and Senate run afoul of treaties and could distort international trade.

“It is important that the U.S. government’s rights over domestic tax policy be exercised in a way that adheres with international obligations to which it has signed-up,” the letter states. It was signed by the countries’ finance ministers.

The letter argues that proposed changes to the U.S. tax code could give American companies an advantage over foreign rivals.

The ministers objected specifically to a new 20% tax on payments from U.S.-based multinationals to their foreign affiliates, saying the measure in the House bill could “discriminate in a manner that would be at odds with international rules.”

They said the provision could also tax the profits of foreign businesses that do not have a permanent base in the U.S.

A second measure also drew objections. It would subject cross-border transfers within banks and finance companies to a 10% tax.

“These two … present [World Trade Organization] problems, said Rebecca Kysar, a professor at Fordham University. She said the measures could be considered to be discriminatory.

The finance ministers said they opposed another measure in the Senate bill that could benefit American companies by subsidizing their exports.

“The way it’s calculated means that the greater the U.S. taxation come from exports, the more of its income gets taxed at 12.5% rate instead of the general corporate tax rate,” said Kysar.

The letter comes at a crucial stage in the legislative process.

The House and Senate have passed competing versions of the tax bill. Their task now is to reconcile major differences between the two measures.

Congressional Republicans are hoping to get the final agreement to President Trump before Christmas.

Trump is expected to deliver remarks on tax reform at the Treasury Department on Wednesday.

Top 5 High Tech Stocks To Own Right Now

March 17, 2017: Markets opened higher again Friday and traded close to the break-even line until about noon when shares started moving higher. Leading indicators and consumer sentiment readings were both strong. Among the sectors, financials weighed while utilities and industrials were showing the best gains. WTI crude oil for April delivery settled at $48.78 a barrel, up just 3 cents on the day, but up 0.6% for the week. April gold added 0.3% on the day to settle at $1,230.20, and up 2.4% for the week. Equities were headed for a higher close shortly before the bell as the DJIA traded up 0.02% for the day, the S&P 500 traded up 0.03%, and the Nasdaq Composite traded up 0.09%.

Stocks traded very near the break-even line just minutes before the closing bell. The closing tally could finish with either a small gain or a small loss for any or all of the indexes.

The DJIA stock posting the largest daily percentage gain ahead of the close Friday was McDonald’s Corp. (NYSE: MCD) which traded up 1.16% at $129.47. The stock’s 52-week range is $110.33 to $131.96. Volume was roughly 30% above the daily average of around 3.5 million shares. The company had no specific news.

Top 5 High Tech Stocks To Own Right Now: Arlington Asset Investment Corp(AI)

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    The first stock on our list today is Arlington Asset Management Corp. (NYSE: AI), which primarily acquires and holds mortgage-related assets. The company’s portfolio consists mostly of agency-backed mortgage-backed securities (MBS) and private-label, residential MBS. The best part is its massive 17.4% dividend yield.

Top 5 High Tech Stocks To Own Right Now: iShares Core S&P Mid-Cap (IJH)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of Lubar & Co., Inc’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Lubar+%26+Co.%2C+Inc

    These are the top 5 holdings of Lubar & Co., IncEnLink Midstream LLC (ENLC) – 1,882,007 shares, 37.97% of the total portfolio. Shares added by 0.40%Hallador Energy Co (HNRG) – 2,788,685 shares, 23.23% of the total portfolio. Vanguard Value ETF – DNQ (VTV) – 77,126 shares, 7.65% of the total portfolio. iShares Core S&P Mid-Cap (IJH) – 38,400 shares, 6.84% of the total portfolio. New PositionVanguard Mid-Cap Value ETF – DNQ (VOE) – 61,550 shares, 6.52% of the tota

Top 5 High Tech Stocks To Own Right Now: DigitalGlobe, Inc(DGI)

Advisors’ Opinion:

  • [By Scott Rubin]

    Stock gainers included DigitalGlobe (NYSE: DGI), which jumped almost 17 percent on a strong earnings report, and B&G Foods, Inc.(NYSE: BGS) which added 13 percent after its Q2 report. Shares of Western Digital (NASDAQ: WDC) lost more than 11 percent after its quarterly earnings results disappointed Wall Street.

  • [By Lisa Levin]

    In trading on Wednesday, telecommunications services shares rose by just 0.03 percent. Meanwhile, top losers in the sector included Internet Initiative Japan Inc. (ADR) (NASDAQ: IIJI), down 4 percent, and DigitalGlobe Inc (NYSE: DGI), down 2 percent.

Top 5 High Tech Stocks To Own Right Now: PDC Energy, Inc.(PDCE)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Names which screen well on a combination of attractive valuation and equitized capital structure, include Outperform rated Apache, Anadarko Petroleum,Gulfport Energy as well as Market Perform rated QEP Resources (QEP) and PDC Energy (PDCE).

  • [By Ben Levisohn]

    Goldman Sachs analyst Brian Singer and team contend that EOG Resources (EOG), Diamondback Energy (FANG), PDC Energy (PDCE), Pioneer Natural Resources (PXD), and RSP Permian (RSPP) can benefit from greater productivity. They explain:

Top 5 High Tech Stocks To Own Right Now: Affimed N.V.(AFMD)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Affimed NV (NASDAQ: AFMD) were down around 21 percent to $1.70. Affimed priced its public offering of 10,000,000 of its common shares at $1.80 per common share.

  • [By Lisa Levin] Gainers
    Marathon Patent Group Inc (NASDAQ: MARA) shares rose 47.1 percent to $3.22 in pre-market trading after jumping 54.23 percent on Wednesday.
    Digital Power Corporation (NYSE: DPW) rose 27.6 percent to $0.800 in pre-market trading after gaining 9.79 percent on Wednesday.
    Social Reality Inc (NASDAQ: SRAX) shares rose 23.1 percent to $7.16 in the pre-market trading session after surging 37.59 percent on Wednesday.
    China Auto Logistics Inc (NASDAQ: CALA) rose 16.9 percent to $4.15 in pre-market trading after gaining 4.11 percent on Wednesday.
    Riot Blockchain Inc (NASDAQ: RIOT) rose 15.1 percent to $18.40 in pre-market trading after climbing 42.01 percent on Wednesday.
    Seven Stars Cloud Group Inc (NASDAQ: SSC) rose 14.5 percent to $2.85 in the pre-market trading session after gaining 0.40 percent on Wednesday.
    Affimed NV (NASDAQ: AFMD) shares rose 14.3 percent to $2.40 in pre-market trading after gaining 4.88 percent on Wednesday.
    Corecivic Inc (NYSE: CXW) rose 10.2 percent to $25.56 in pre-market trading after climbing 0.65 percent on Wednesday.
    LM Funding America, Inc. (NASDAQ: LMFA) rose 9.6 percent to $3.30 in pre-market trading after surging 34.98 percent on Wednesday.
    U.S. Global Investors, Inc. (NASDAQ: GROW) rose 7.2 percent to $3.30 in pre-market trading after dropping 8.06 percent on Wednesday.
    Xunlei Ltd (NASDAQ: XNET) rose 6.8 percent to $25.61 in pre-market trading after climbing 11.74 percent on Wednesday.
    Net 1 UEPS Technologies Inc (NASDAQ: UEPS) shares rose 5.9 percent to $13.00 in pre-market trading after gaining 21.34 percent on Wednesday.
    Addus Homecare Corporation (NASDAQ: ADUS) rose 5.5 percent to $35.60 in pre-market trading after gaining 3.69 percent on Wednesday.
    TOP SHIPS Inc (NASDAQ: TOPS) rose 5.2 percent to $0.528 in pre-market trading after falling 10.36 percent on Wednesday.
    Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) rose 4.7 percent to $14.11 in pre-market trading. Teva Pharma

The Week Ahead: The Year's Biggest Biotech Conference, Host Of IPO Quiet Period Expirations, An

Related DGLY 36 Biggest Movers From Yesterday 30 Stocks Moving In Tuesday's Mid-Day Session

Below is a list of notable corporate events for the week beginning December 11. Note, this list is not comprehensive and all dates are subject to change.

Monday

Conferences

American Society of Hematology (ASH) Meeting Dec. 9 thru Dec. 12

Notable Earnings

Casey’s General Stores, Inc (NASDAQ: CASY) Q2 after hours

Secondary Offering Lockup Expirations

Athenex, Inc (NASDAQ: ATNX)

IPO Quiet Period Expirations

Altair Engineering Inc (NADAQ: ALTR)
Loma Negra Compania Industrial Argentina Sociedad Anonima (NYSE: LOMA)
SendGrid, Inc (NYSE: SEND)
Arsanis, Inc (NASDAQ: ASNS)

Analyst/Investor Days

Coupa Software Incorporated (NASDAQ: COUP)
Equifax Inc (NYSE: EFX) in New York

Annual Shareholder Meetings

1-800-Flowers.com, Inc (NASDAQ: FLWS)
Cicso Systems, Inc (NASDAQ: CSCO)

Tuesday

Economic Data

API U.S. Crude Oil Inventories released after market close

Notable Earnings

VeriFone Systems, Inc (NYSE: PAY) Q4 after hours

Secondary Offering Lockup Expirations

ADOMANI, Inc (NASDAQ: ADOM)

IPO Quiet Period Expirations

Funko, Inc (NASDAQ: FNKO)
Evoqua Water Technologies Corp (NYSE: AQUA)
Allena Pharmaceuticals, Inc (NASDAQ: ALNA)
Stitch Fix, Inc (NASDAQ: SFIX)
Bluegreen Vacations Corporation (NYSE: BXG)
SailPoint Technologies Holdings, Inc (NYSE: SAIL)
Level Brands, Inc (NYSE: LEVB)

Analyst/Investor Days

Equifax in Toronto
Arthur J. Gallagher & Co (NYSE: AJG)

Wednesday

Economic Data

EIA Crude Oil Inventories 10:30 a.m. ET

Notable Earnings

Pier 1 Imports, Inc (NYSE: PIR) Q3 after hours

Secondary Offering Lockup Expirations

Boston Omaha Corporation (NASDAQ: BOMN)

Analyst/Investor Days

Equifax In Montreal
LendingTree, Inc (NASDAQ: TREE)
Iovance Biotherapeutics, Inc (NASDAQ: IOVA)
The Charles Schwab Corporation (NYSE: SCHW) business update call

Annual Shareholder Meetings

United Natural Foods, Inc (NASDAQ: UNFI)
Fireside Chat with Dan Gilbert and Kynikos Associates’ Jim Chanos 2 p.m. ET in Detroit

IPOs

Adial Pharmaceuticals (ADIL)

Thursday
Economic Data

EIA Natural Gas Inventories 10:30 a.m. ET
FCC to hold Net Neutrality vote

Notable Earnings

Adobe Systems Incorporated (NASDAQ: ADBE) Q4 after hours
Costco Wholesale Corporation (NASDAQ: COST) Q1 after hours
Oracle Corporation (NYSE: ORCL) Q2 after hours

IPOs

Casa Systems (CASA)

Analyst/Investor Days

Finjan Holdings, Inc (NASDAQ: FNJN)
Danaher Corporation (NYSE: DHR)
Delta Air Lines, Inc (NYSE: DAL)
Deckers Outdoor Corporation (NYSE: DECK) annual shareholder meeting, to vote on Marcato Capital board nominees

Legal

Axon Enterprise, Inc (NASDAQ: AAXN) and Digital Ally, Inc (NASDAQ: DGLY) to meet in court to discuss patent trial schedule
AOL Instant Messenger to be decommissioned
Friday

Economic Data

U.S. Credit Card delinquencies
Baker Hughes Oil Rig Counts expected 1pm ET

Analyst/Investor Days

MetLife, Inc (NYSE: MET) business update call

IPOs

Newmark Group (NMRK)

M&A

QUALCOMM Incorporated (NASDAQ: QCOM) tender offer for NXPSemiconductors (NASDAQ: NXPI) expires 5 p.m. ET

Is Trump making older people look bad?

This article is reprinted by permission from NextAvenue.org.

In his recent op-ed piece, Time to take baby boomers off the ticket, Washington Post columnist David Von Drehle argued that no thriving society finds its fresh thinking among its oldest leaders. By this, Von Drehle, 56, meant that the highest seat in U.S. office should be saved for those around 50 or younger a bold case.

This notion was of course sparked by the fact that the current U.S. president is its oldest-when-elected, 71-year-old Donald Trump, who was 70 when he won.

The four presidents Von Drehle says are widely-regarded as the best George Washington, Abraham Lincoln, Theodore Roosevelt and Franklin D. Roosevelt all took office around, or under, the age of 50. He thinks thats a telling link between age and ability.

Why am I reading about potential candidates for 2020 who will be in their 70s? Von Drehle lamented, citing possible future Democratic candidates like Joe Biden, Sen. Bernie Sanders and Sen. Elizabeth Warren, who are all either in their 70s or would be in 2020.

The wisdom of years is a check, not an engine, he wrote. Though age takes its toll in different ways on different people, in the aggregate the science is clear: Mental agility, executive function and creativity all tend to decline as we pass through middle age.

Von Drehle, who wrote a book about Lincoln, said he yearns for leaders at the peak of their creative and conceptual powers who reflect the body of people most affected by the presidents decisions in the long run.

Decisions that will shape lives long after the baby boomers are gone should not be made by boomers and their older siblings. Were passing a lot of red ink and unsolved problems to the next generation. We should pass the torch, too, wrote Von Drehle.

Anti-Trump sentiment: fuel for ageism?

According to NPR, Trump has thelowest job-approval ratingof any president in modern polling. He has lingered around 39% approval since taking office. Its possible that Trump is giving 70-year-olds a bad name in the eyes of most Americans, and its also possible that Americans perhaps Von Drehle in his column are making unfair connections between Trumps behavior and his age.

At Next Avenue, weve done enough reporting about people over 50 to know that ageism is deeply and widely embedded into our culture. Its pervasive in thetech industry,health careandthe words we use. Ageism is everywhere. Its the last socially acceptable prejudice. Not often enough are we conscious of how the way we speak, think and act reinforces stereotypes and misjudgments about older people.

While more attention was drawn toHillary Clintons agethan Trumps during the election campaign, people sometimes use age and the results of age asammunition against Trump, too. Some have even said Trump has dementia or pre-dementia.

Is it fair to criticize and question the president? Of course. Democracy runs on it. But is it OK to center your gripes around the presidents age and perceived intellectual capacity because of it? Are those aspects of objection as valid as say, his policy decisions or his treatment of others? Would Trump really have been a different president at age 40 or 50 than the one he is now?

Certainly, 70-year-olds canrun triathlons, becabaret singersandfight for womens rights. Its not so far-fetched to think a 70-year-old could make a solid president and successfully run a prosperous and equitable nation.

Before coming to Next Avenue, Grace was the associate editor and social media manager for two different trade magazines at Macfadden Communications Group in New York.Grace graduated from the University of Minnesota-Twin Cities with a BA in journalism and minor in gender, women and sexuality studies, and she was the editor in chief of the University of Minnesotas student magazine, The Wake.She volunteers as an editor for the local feminist quarterly, The Riveter Magazine. Reach her by email atgbirnstengel@nextavenue.org.

This article is reprinted by permission from NextAvenue.org, 漏 2017 Twin Cities Public Television, Inc. All rights reserved.

Top 5 Gold Stocks To Invest In 2018

Forget about boring stocks. Bitcoin is where it’s at these days for investors.

The virtual currency is now trading at a record high above $8,200 — just a little more than a month after bitcoin first passed the $5,000 level. If this keeps up, bitcoin could be trading at $10,000 before the end of the year.

The price of one bitcoin (XBT) has surged more than 735% this year alone and has skyrocketed nearly 40,000% in the past five years.

Of course, bitcoin’s meteoric rise has led to some skepticism. JPMorgan Chase (JPM) CEO Jamie Dimon has bashed it on numerous occasions, calling it a “fraud” that’s better off being used by drug dealers and North Korea.

And Saudi Prince Alwaleed, a billionaire whose Kingdom Holding Company owns stakes in Apple (AAPL, Tech30) and Citigroup (C), told CNBC before he was arrested in a sweeping anti-corruption probe that he thought bitcoin was an “Enron in the making” that will implode.

But while some see a bubble about to burst, others see opportunity. Lloyd Blankfein, the CEO of JPMorgan Chase rival Goldman Sachs (GS), took issue with bitcoin critics.

Top 5 Gold Stocks To Invest In 2018: Brookfield Renewable Powerr Fund(BEP)

Advisors’ Opinion:

  • [By Federico Zaldua]

    I expect the Brookfield Group of Companies, which is composed of no fewer than 15 publicly traded entities, to be very active acquisitive in the near-term future. Here I focus my attention on three members of the Brookfield Group that are going to be the most active with M&A. While Brookfield Asset Management (BAM) will concentrate its M&A efforts into all geographies and all asset classes, Brookfield Renewable Energy Partners (BEP) and Brookfield Infrastructure Partners (BIP) will concentrate on their respective industries. Let’s see whether you should go long on any of this separate -although related – entities.

    Good Operational Performance

    Brookfield Asset Management, held by Lou Simpson and Ron Baron, counts with a liquidity position of more than $5 billion at the parent and principal subsidiaries along with nearly $10 billion drawable private fund commitments. More importantly, the company has expressed its interest into using this liquidity to make acquisitions. Management clearly stated in its letter to shareholders:

Top 5 Gold Stocks To Invest In 2018: Grifols, S.A.(GRFS)

Advisors’ Opinion:

  • [By Monica Wolfe]

    Grifols SA (GRFS)

    Paulsons fourth largest holding is in Grifols SA where he holds on to 19,786,279 shares of the companys stock. His position in the company represents 4% of his total portfolio and 5.76% of the companys shares outstanding.

Top 5 Gold Stocks To Invest In 2018: CF Industries Holdings, Inc.(CF)

Advisors’ Opinion:

  • [By Shanthi Rexaline]

    Agri-Input Companies — Seeds/ Fertilizers/Pesticides Manufacturers

    Monsanto Company (NYSE: MON): +68.82 percent since 2011. Syngenta AG (ADR) (NYSE: SYT): +56.26 percent since 2011. Mosaic Co (NYSE: MOS): -63.1 percent since 2011. Potash Corporation of Saskatchewan (USA) (NYSE: POT): -67.8 percent since 2011. CF Industries Holdings, Inc. (NYSE: CF): +5.04 percent since 2011. Agrium Inc. (USA) (NYSE: AGU): +1.10 percent since 2011.

    Agri-Finance Companies

  • [By Lisa Levin]

    In trading on Tuesday, basic materials shares fell 0.63 percent. Meanwhile, top losers in the sector included Myers Industries, Inc. (NYSE: MYE), down 7 percent, and CF Industries Holdings, Inc. (NYSE: CF) down 6 percent.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Monday was CF Industries Holdings, Inc. (NYSE: CF) which jumped 3.7% to $30.37. The stocks 52-week range is $20.77 to $37.17. Volume was 5.3 million which is just under the daily average of around 5.4 million shares.

  • [By Ben Levisohn]

    CF Industries Holdings (CF) has climbed 3.3% to $30.25 after getting upgraded to Buy from Neutral at Goldman Sachs.

    Nektar Therapeutics (NKTR) has soared 21% to $18.80 after positive results from a pain-killer trial.

  • [By Ben Levisohn]

    CF Industries (CF) rose to the top of the S&P 500 today, continuing strength that began earlier this month.

    Getty Images

    CF Industries gained 6.9% to $28.96 today, while the S&P 500 fell 0.2% to 2,181.90. CF Industries has gained 21% in November.

    Despite the rally, CF Industries is still down 29% this year, and as recently as Nov.3, Citigroup’s P.J. Juvekar and team were writing that the fertilizer company was “looking more like a 2008 story” after weaker-than-expected earnings. Donald Trump’s election victory, however, has jumpstarted CF Industries and prompted FBN technical analystJC OHara to list it among the top-50 stocks following Trump’s election, noting that “we want to own the stocks that were first to leave the gate…New Momentum should continue.” On Nov. 9, Barron’s Michael Kahn agreed, writing that “CF Industries does merit a look.”

    CF Industries reported net income of $700 million on sales of $4.3 billion in 2015. Its market capitalization rose to $6.8 billion today from $6.3 billion yesterday.

     

Top 5 Gold Stocks To Invest In 2018: Exterran Corporation(EXTN)

Advisors’ Opinion:

  • [By Dustin Parrett]

    Company Name

    Share PriceYTDMarket CapClayton Williams Energy Inc. (NYSE: CWEI)$138.8216.4%2.4BDiamondback Energy Inc. (Nasdaq: FANG)$106.365.42%$9.38BWestern Gas Partners LP (NYSE: WES)$65.6411.71%$9.67BTesoro Logistics LP (NYSE: TLLP)$59.3416.79%$6.25BResolute Energy Corp. (NYSE: REN)$46.0811.87%$931.13MAntero Midstream Partners LP (NYSE: AM)$34.9813.28%$6.4BExterran Corp. (NYSE: EXTN)$33.9942.22%$1.19BDominion Midstream Partners LP (NYSE: DM)$32.9011.34%$2.6BNextEra Energy Partners LP (NYSE: NEP)$31.1922.12%$1.68BArchrock Inc. (NYSE: AROC)$16.0021.21%$1.12B

    While some of these stocks have performed well, we arent recommending this list of natural gas stocks. Thats because we arent interested in stocks that have already peaked at Money Morning; were interested in the next big winner. And we have one that could surge in 2017

Top 5 Gold Stocks To Invest In 2018: Endocyte, Inc.(ECYT)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Carl Icahn has big plans for the US auto-parts sector — and big retailers like AutoZone (NYSE: AZO), O’Reilly Automotive (NASDAQ: ORLY) and Advance Auto Parts (NYSE: AAP) aren’t going to like them: Link

    ECONOMIC DATA
    USA Unit Labor Costs (QoQ) for Q1 2.20% vs 2.50% consensus estimate. Nonfarm Productivity (QoQ) for Q1 0.00% vs -0.20% consensus estimate.
    US Services Purchasing Managers' Index for May is schedule for release at 9:45 a.m. ET.
    Data on factory orders for April will be released at 10:00 a.m. ET.
    The ISM non-manufacturing index for May is schedule for release at 10:00 a.m. ET.
    The labor market conditions index for May will be released at 10:00 a.m. ET.
    The Treasury is set to auction 3-and 6-month bills at 11:30 a.m. ET.
    The TD Ameritrade Investor Movement Index for May is schedule for release at 12:30 p.m. ET.
    ANALYST RATINGS
    HSBC upgraded Chevron (NYSE: CVX) from Hold to Buy
    Susquehanna upgraded Skechers (NYSE: SKX) from Neutral to Positive
    Deutsche Bank upgraded WEX (NYSE: WEX) from Hold to Buy
    Pacific Crest downgraded Apple from Overweight to Sector Weight
    RBC downgraded Perrigo (NYSE: PRGO) from Sector Perform to Underperform
    Wedbush downgraded Endocyte (NASDAQ: ECYT) from Outperform to Neutral

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here or email minutes@benzinga.com.

  • [By Lisa Levin]

    Shares of Endocyte, Inc. (NASDAQ: ECYT) were down 31 percent to $1.89 after the company issued clinical updates for EC1456 and EC1169, and announced plans to reduce workforce by 40 percent via restructuring. Endocyte said that it is continuing EC1169 program in taxane-exposed patients, but ending clinical development of EC1456 and EC1169 in taxane-na茂ve patients.

42% of parents would send their kids abroad for college. But it ain’t cheap

HSBC has good news for teenagers who want to get far, far away from their parents.

A new survey published by the bank shows that 42% of parents would consider sending their kids abroad for college, up from 35% in 2016.

Interest in an international education — which can be very expensive — has increased in almost all of the 15 countries and territories included in the survey.

Parents in China, Hong Kong, India, Malaysia, Indonesia and the United Arab Emirates were the most enthusiastic, with a majority in each saying they would consider sending their kids abroad for college.

British, Australian and French parents were less keen, with only 17% to 22% expressing an interest in international study. The figure was 36% among American parents.

student international usa turkey study abroad The U.S. remains the most popular destination for international students.

Parents said the U.S. was the most desirable place for their kids to study, followed by Australia and the U.K.

Some families could be in for major sticker shock — especially if they’ve set their sights on an American education.

HSBC said that international parents expect tuition at U.S. colleges to be $11,000 a year or less. In reality, the tuition costs are closer to $33,000 a year.

The bank said that total costs over four years, including living expenses, average more than $180,000 at major U.S. universities.

International students typically pay full tuition at American universities.

5 stunning stats about college debt 5 stunning stats about college debt

Here are a few more key numbers from the study:

– 60% of parents said they’d be open to having their child complete a degree that is either completely or partly online.

– 68% of parents said they are confident their kid will get a great job, with Indians being the most optimistic at 85%. That number drops to only 36% among parents in France.

– 93% of Chinese parents said they have paid for private tuition or tutoring, the highest of any country. Only 23% of British parents said they’ve done the same.

The HSBC report surveyed nearly 8,500 parents in 15 countries and territories.

4 Growth Stocks to Pick From a Choppy MedTech Market

The U.S. investment space has been fraught with uncertainties of late. The healthcare industry, in particular, has been facing multiple issues, with the Obamacare-repeal saga dominating the headlines. However, President Trump’s proposed policies to abolish the infamous 2.3% medical device sales tax, a key part of the Affordable Care Act, have kindled hope in the MedTech space. Notably, this tax has been suspended for two years and is supposed to be put into effect again on Jan 1, 2018.

4 Growth Stocks to Pick From a Choppy MedTech Marketinvestorplace.com/wp-content/uploads/2015/10/medical-devices-53×40.jpg 53w, investorplace.com/wp-content/uploads/2015/10/medical-devices-40×30.jpg 40w, investorplace.com/wp-content/uploads/2015/10/medical-devices-250×187.jpg 250w, investorplace.com/wp-content/uploads/2015/10/medical-devices-200×150.jpg 200w, investorplace.com/wp-content/uploads/2015/10/medical-devices-160×120.jpg 160w, investorplace.com/wp-content/uploads/2015/10/medical-devices-65×49.jpg 65w, investorplace.com/wp-content/uploads/2015/10/medical-devices-100×75.jpg 100w, investorplace.com/wp-content/uploads/2015/10/medical-devices-150×112.jpg 150w,https://investorplace.com/wp-content/uploads/2015/10/medical-devices-107×80.jpg 107w, investorplace.com/wp-content/uploads/2015/10/medical-devices-167×125.jpg 167w, investorplace.com/wp-content/uploads/2015/10/medical-devices-67×50.jpg 67w, investorplace.com/wp-content/uploads/2015/10/medical-devices-78×58.jpg 78w” sizes=”(max-width: 259px) 100vw, 259px” />

Such high taxes forced companies to lay off employees, limit research and development activities and reduce capital investment. However, a recently-proposed legislation looks to extend the suspension of the medical device tax for another five years. This has undoubtedly been the latest buzz in the MedTech space.

How Will the Tax Suspension Help MedTech?

“The tax code is a monstrosity and there’s only one thing to do with it. Scrap it, kill it, drive a stake through its heart, bury it and hope it never rises again to terrorize the American people.” — Steve Forbes

AdvaMed, a leading American medical device trade association, had referred to the medical device tax as a ‘significant drag on medical innovation’. Small device companies have suffered the most owing to this. Amid such worries, a repeal of the tax paradigm is expected to boost the pace of hiring and investment among the 9,000 America-based medical device manufacturers, instilling investor confidence in the stocks.

In line with the latest legislation, a report by The Joint Committee on Taxation as published in Forbes in the article written by Bruce Japsen suggests that the Internal Revenue Service collected taxes in the range of $1 billion to $2 billion per year in 2013, 2014 and 2015. This repealing of the medical device tax will cost the U.S. Treasury around $20 billion over a decade.

AdvaMed’s CEO Scott Whitaker said that during 2016 and 2017, MedTech players have been able to reinvest a huge amount in innovation that would otherwise have been paid as taxes.

Further, according to a report by Joe Panetta, Biocom’s president and CEO, the Congress must repeal the tax immediately which impedes innovation, jobs, economic growth and delays patient access to medical technology. This is also necessary to ensure that MedTech sectors continue with research and development and reinvest in innovation.

How is MedTech Positioned?

Though Medtech is faced with intense volatility, there are bountiful opportunities in the space. Per Centers for Medicare and Medicaid Services report published by Advisory Board, U.S. health care spending is estimated to reach approximately $5.5 trillion by 2025, representing 19.9% of Gross Domestic Product (based on assumptions that the Affordable Care Act will continue through 2025).

In the view of this, investors should ideally pick stocks that have the potential to safeguard portfolios from market volatility.

Our Screening Parameters

In order to save investors the time-taking process of identifying the best performing MedTech stocks, we have taken the help of the Zacks Stock Screener.

We also chose stocks that boast a Zacks Rank #1 (Strong Buy) or 2 (Buy).

We have selected stocks that have a favorable Growth Style Score of A or B. Our research shows that stocks with Style Scores of A or B, when combined with a Zacks Rank #1 or 2, offer the best investment opportunities. Furthermore, the selected stocks boast a VGM Score of A or B.

Under the Zack Style Score system, V stands for Value, G for Growth and M for Momentum. The VGM Score is simply a weighted combination of these parameters and is a comprehensive tool that allows investors to filter through the standard scoring system and pick the winning stocks.

Apart from this, we have filtered out MedTech stocks with attractive long-term (three-to-five years) earnings growth rate as well as impressive earnings and sales growth rates for the current fiscal. Strong fundamentals, strategic implementation, planned execution and certain other positive factors show that these shortlisted performers carry substantial upside potential.

Accordingly, we have zeroed in on the following stocks:

Growth Stocks to Pick From a Choppy MedTech Market: Chemed Corporation (CHE)

Chemed Corporation (NYSE:CHE) is a provider of end-of-life hospice care services through its VITAS Healthcare Corporation subsidiary. This Zacks Rank #2 company has a long-term expected earnings growth rate of 10% and a Growth Score of A. You can see the complete list of today’s Zacks #1 Rank stocks here.

Chemed currently operates through two wholly-owned subsidiaries, namely, VITAS Healthcare Corporation — a major provider of end-of-life care — and Roto-Rooter, a leading commercial and residential plumbing and drain cleaning service provider. The company’s subsidiaries saw year-over-year revenue growth in the third quarter. Also, the guidance raise backed by the company’s expectations of significant gains from its Roto-Rooter business buoys optimism. This business has witnessed consistent growth on strong performance by the core plumbing and drain cleaning service segments as well as solid growth in water restoration.

The stock’s projected EPS growth rate for the current year is 15.8%, as against the broader industry’s estimated decline of 4.6%. The stock has gained 49.1% over a year, better than the broader industry’s decline of 4.9%. The company has a VGM Score of A and a Growth Score of A.

Growth Stocks to Pick From a Choppy MedTech Market: Natus Medical Inc (BABY)

Natus Medical Inc (NASDAQ:BABY) is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care.

The company recently announced the buyout of certain neurosurgery business assets from Integra LifeSciences. According to the company, the buyout includes the global Camino ICP monitoring product line, including its San Diego manufacturing facility, and the U.S. rights relating to Integra’s fixed pressure shunts and U.S. rights to Codman’s DURAFORM dural graft implant, standard EVD catheters and CSF collection systems.

The company carries a Zacks Rank #2 and a VGM Score of B. The projected sales growth rate for the current year stands at 34.9% compared with the broader industry’s estimated gain of 2.4%.The stock has gained 14.2% over the last six months, higher than the broader industry’s 4.5%.

Growth Stocks to Pick From a Choppy MedTech Market: Cogentix Medical Inc (CGNT)

Cogentix Medical Inc (NASDAQ:CGNT) is a medical device company which designs, develops, manufactures and markets proprietary technologies for the urology market.

The company recently acquired Genesis Medical. The acquisition will add $0.8 million to revenues in the second half of the year and more than $2 million in the next year.

The company has a Zacks Rank #2. The stock has a Growth Score of A and VGM Score of B. It has gained 64.8% over the last six months, compared with the broader industry’s 4.5%. The projected EPS growth rate for the year stands at 96.3% compared with the broader industry’s 16%.

Growth Stocks to Pick From a Choppy MedTech Market: LivaNova PLC (LIVN)

LivaNova PLC (NASDAQ:LIVN) is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The company recently announced the receipt of FDA approval for its latest Vagus Nerve Stimulation Therapy System.

The system consists of the SenTiva implantable generator and the next-generation VNS Therapy Programming System for the treatment of patients with drug-resistant epilepsy.

This Zacks Rank #2 stock promises long-term earnings growth of 10%. Notably, LivaNova has a Growth Score of B and VGM Score of B. The stock has gained 33.7% over the last six months, higher than the broader industry’s 4.5% gain.

Zacks Editor-in-Chief Goes “All In” on This Stock

Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Download it free >>

Compare Brokers

This is why almost everyone should invest in small-cap value funds

Over the past few years I have become more and more convinced that for many investors perhaps even most investors can benefit from focusing on small-cap value funds in their equity portfolios.

Small-cap value funds combine smaller companies (which historically tend to grow much faster than larger ones) and value companies, which have a long history (ironically) of outgrowing growth companies.

To make sure were on the same page, I want to define our terms.

A small-cap stock is generally a company with a market capitalization of between $300 million and $2 billion, although there are funds called small cap in which the average size company is higher.

Value companies are often regarded as ones that are out of favor with institutional investors. The measure of a company on the growth-to-value spectrum is usually the price-to-book ratio, and sometimes the price/earnings ratio.

Lower ratios indicate deeper discounts (bargains in the stock market, in other words) and higher expected returns.

The price/earnings ratio of the average small-cap growth fund is 28.3, vs. 19.8 for small-cap value funds. The average price-to-book ratio of small-cap growth funds is 3.7, vs. 1.7 for small-cap value funds.

Not surprisingly, small-cap value stocks have historically outproduced other major asset classes.

Lots of investors and advisers worry about the volatility of small-cap value stocks. But the best research I know has led me to believe that this worry is overblown.

When I recommend small-cap value funds, some people seem to think Im trying to lead investors over a cliff in search of high returns without regard to risk. Not true.

Personally, I am risk-averse. I take every risk extremely seriously, and I am willing to work hard to eliminate those that I can.

I have absolutely no desire to advocate high-risk investments, unless theres a high probability for significantly higher returns.

Its important to understand that risk comes in more than one flavor.

For many investors, the risk of inflation hence the risk of returns that are too low is considerably more significant than the risk of short-term bumps in the road.

When youre invested in the stock market, theres no way you can completely avoid risk.

If you think of the stock market as the S&P 500 index
SPX, -0.26%
you could think of the risk of that index as normal.

Long-term small-cap value returns have been higher than this normal, and the risks have been higher as well.

But when you drill down into the data, you find that the short-term risks from small-cap value investing have been only 2% to 5% more, while long-term returns have been much higher.

I always prefer to back my assertions with data, and fortunately we have nearly 90 years of it, going back to 1928.

Lets look at two major asset classes: large-cap blend (like the S&P 500) and small-cap value.

From 1928 through 2016, the S&P 500 index compounded at 9.7%, while small-cap value stocks grew at 13.5%.

To achieve returns like those, investors had to persevere through some pretty difficult years. In that long period, the worst calendar-year losses were 43.3% for the S&P 500 and 55.5% for small-cap value stocks in each case the year was 1931.

That comparison is no surprise to those who understand that return and risk go together.

But if youre being warned about the worst of times, its only fair to contemplate the best of times, too.

The highest one-year returns came just two years later, in 1933, with gains of 54% for the S&P 500 and 125% for small-cap value stocks. (And the investors who bailed out of the market after 1931, perhaps vowing never again, missed out on those big 1933 gains.)

Long-term investing, of course, doesnt center on single-year returns. For many investors, a 40-year span is reasonable, especially since many people will have money invested for 25 or more years after they retire.

Fortunately, we have data that lets us look at every 40-year period since 1928. I think the numbers are very instructive.

Taking all those periods into account, the S&P 500s average 40-year return was 10.9%, considerably less than the 16.2% average for small-cap value stocks.

The best 40-year period: 12.5% for the S&P 500 and 19% for small-cap value. The worst 40-year period returns were 8.9% and 11.6%, respectively.

Look at those numbers again, and youll see that the very worst 40-year record for small-cap value stocks (11.6%) was nearly as high as the very best record for the S&P 500 (12.5%).

The results were more variable with individual years. In fact, there were eight single years in which the S&P 500 made money and small-cap value stocks had losses. But on the other hand, in four of the 24 years in which the S&P 500 lost money, small-cap value stocks actually made money.

Heres a point that should not be overlooked: For long-term investors (40 years or more), all these losses were temporary. Yet the long-term gains were permanent, at least for those who stayed the course.

Applying average 40-year returns to an initial investment of $1,000, we get ending values of $62,699 in the S&P 500, vs. $405,737 in small-cap value stocks.

To my mind, this is life-changing information, even when it is applied to only part of a portfolio.

I would like nothing better than to get this information and these insights into the hands of trustees of corporate 401(k) plans.

I have reviewed more than 100 such plans, and many dont even offer small-cap funds, let alone small-cap value funds.

Read: 10 things successful investors dont do

Yet when employees are being denied traditional pensions and told to make their own investment choices, I cannot think of any sensible rationale for depriving them of investment options that could make the kind of long-term differences weve seen in small-cap stock funds.

So if youre an individual, what should you do?

If youre in a retirement plan that offers one or more small-cap value funds, I think you should have some part of your money in those funds, even if the rest is in a target-date retirement fund. Heres an article on that idea.

If your retirement plan does not offer small-cap value, then you should consider diverting some of your savings to an IRA, where youll be able to choose a low-cost small-cap value index fund or ETF. (Dont divert savings until you have maximized whatever employer match youre entitled to, however.)

Read: How to talk to your family about your estate plan

Heres one more interesting point about small-cap value stocks: Some recent research by my colleague Chris Pederson shows that this asset class recovers from adversity more quickly than the S&P 500.

His report is titled Resiliency How Fast Do Different Asset Classes Recover? Its worth reading.

For more on small-cap value investing, listen to my podcast: 10 reasons small cap value is a life changer.

Richard Buck contributed to this article.

Best Low Price Stocks To Buy Right Now

A few weeks ago, we published an article that characterized Gilead (GILD) as a “Value Trap.” That article was a follow-up to an earlier article which used our work on Gilead as an example of how a solid conceptual framework could help investors make better decisions. Both of these articles were based on a 16-page valuation report on Gilead we published to our members in September, 2016.

We caught a lot of flack for the recent characterization of Gilead as a value trap, but our opinion was redeemed on February 7th, when the stock fell heavily after a disappointing earnings announcement.

In today’s article, we’ll take another look at the valuation process – the most important weapon in an investor’s arsenal – in a continuation of the Gilead example. We would invite new readers to read through each of the earlier articles as well, to get a picture of the overall process!

Investing Anecdotes are Dangerous!

What interested us in September 2016, when we made our original analysis of Gilead, was the noise among the value investing community about what a deal Gilead was because the stock was trading at such a low Price-to-Earnings (P/E) ratio (See our article Three Things You Should Know About Gilead).

Best Low Price Stocks To Buy Right Now: Astrotech Corporation(ASTC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Astrotech Corp (NASDAQ: ASTC) shares shot up 70 percent to $4.83. Astrotech reported that it has completed its successful 1st Detect demo with Department of Homeland Security and Transportation Security Administration personnel.

  • [By Lisa Levin]

    Astrotech Corp (NASDAQ: ASTC) shares shot up 60 percent to $4.37. Astrotech reported that it has completed its successful 1st Detect demo with Department of Homeland Security and Transportation Security Administration personnel.

  • [By William Romov]

    Last Wednesday (Dec. 6), the company received a patent for certain methods of production of its phase 2 antidepressant, AV-101.

    Penny Stock Current Share Price Dec. 4 – Dec. 8 Gain (as of Dec. 8)
    VistaGen Therapeutics Inc. (Nasdaq: VTGN) $1.80 135%
    FXCM Inc. (Nasdaq: GLBR) $1.12 124%
    Neuralstem Inc. (Nasdaq: CUR) $2.00 75.44%
    Ohr Pharmaceuticals Inc. (Nasdaq: OHRP) $1.49 75.29%
    ClearSign Combustion Corp. (Nasdaq: CLIR) $3.50 53.85%
    Astrotech Corp. (Nasdaq: ASTC) $4.21 51.99%
    Burcon NutraScience Corp. (Nasdaq: BUR) $0.72 44%
    LM Funding America Inc. (Nasdaq: LMFA) $3.72 42.53%
    Second Sight Medical Products Inc. (Nasdaq: EYES) $1.75 42.28%
    Globus Maritime Ltd. (Nasdaq: GLBS) $1.47 41.35%

    As a result, its share price shot up from $0.92 to $2.52 on Wednesday. The stock pulled back to $1.80 by the end of the week, for a total gain of 135% for the week.

Best Low Price Stocks To Buy Right Now: Universal Health Services, Inc.(UHS)

Advisors’ Opinion:

  • [By Paul Ausick]

    Universal Health Services Inc. (NYSE: UHS) lost 8.4% Wednesday to post a new 52-week low of $1/99.81 after closing Tuesday at $108.99. The 52-week high is $139.77. Volume of around 5.8 million was nearly 6 times the daily average of around 1 million shares traded. Raymond James downgraded the stock this morning on news of another request for information from the company related to a federal investigation.

  • [By Ben Levisohn]

    Universal Health Services (UHS), yesterday’s biggest loser, soared to the top of the S&P 500 today as it rebounded from the massive selloff.

    Agence France-Presse/Getty Images

    Universal Health Servicesgained 6.9% to $108.57 today, while the S&P 500 rose 0.4% to 2,262.03.

    Weakness in Universal Health Services began when Buzzfeed ran an article last week, contending the companys psychiatric hospitals put profits ahead of people. Yesterday, it tumbled when Raymond James cut its rating on the stock due to problems that could be caused by a potential Senate investigation.

    Universal Health Services’ market capitalization rose to $10.5 today from $9.8 billion yesterday, nearly recouping its drop from $10.6 billion on Dec. 13.

    It reported net income of $680 million on sales of $9 billion in 2015.

  • [By Ben Levisohn]

    Universal Health Services (UHS) slumped to the bottom of the S&P 500 today after getting downgraded by Raymond James.

    Pixabay

    Universal Health Servicesdropped 6.8% to $101.55 today, while the S&P 500 fell 0.8% to 2,253.28.

    Raymond James analyst John Ransom and team explain why they cut Universal Health Services to Market Perform from Outperform:

    We are lowering our rating onUniversal Health Services to a Market Perform (from an Outperform) due to an escalation in events surrounding last weeks Buzzfeed article. Last Friday (12/9), Senator Grassley, Chair of the Judiciary Committee, sent a letter…to the office of inspector general regarding details of the current federal investigation into Universal Health Services. Specifically, the letter rehashes the Buzzfeed article and requests an update on the investigation by Dec. 23. Our view is that – even ifUniversal Health Services management is correct on the legalities – we think the entrance of the venerable Senator Grassley into the mix takes the political risk to a more dangerous level. Plus – even if “suicide ideation” doesn’t generate additional revenues per admission, we think it’s possible that the heightened political scrutiny could invite more caution and/or red tape into the admissions process – either externally or from self-policing. Add in the ongoing OIG investigation, and we think the risk-reward is no longer compelling.

    Universal Health Services’ market capitalization fell to $9.8 billion today from $10.6 billion yesterday. It reported net income of $680 million on sales of $9 billion in 2015.

  • [By Benzinga News Desk]

    Goldman Sachs (NYSE: GS) has at least one billion reasons to hope President Trump’s paring back of Dodd-Frank will include the Volcker Rule: Link

    ECONOMIC DATA
    10:30 a.m. Dallas Fed Manufacturing Business Index
    11:30 a.m. 6-Month Bill Auction
    11:30 a.m. 3-Month Bill Auction
    1 p.m. 2-Year Note Auction
    1:15 p.m. Chicago Fed President Evans Speaks
    6:30 p.m. FOMC Member Kaplan Speaks
    ANALYST RATINGS
    Piper Jaffray upgraded Best Buy Co (NYSE: BBY) from Neutral to Overweight
    Wells Fargo upgraded Allscripts Healthcare (NASDAQ: MDRX) from Market Perform to Outperform
    Mizuho upgraded Universal Health Service (NYSE: UHS) from Neutral to Buy
    Piper Jaffray downgraded The Michaels Companies (NASDAQ: MIK) from Overweight to Neutral
    JMP Securities downgraded KB Home (NYSE: KBH) from Market Outperform to Market Perform
    Raymond James downgraded Sierra Wireless Inc. (NASDAQ: SWIR) from Outperform to Market Perform

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here or email minutes@benzinga.com.

  • [By Ben Levisohn]

    Universal Health Services (UHS) tumbled to the bottom of the S&P 500 today after BuzzFeed published an investigative story alleging that the company’s psychiatric hospitals put profits ahead of people.

    Getty Images

    Shares of Universal Health Services dropped 12% to$111.30 today, while the S&P 500 rose 1.3% to 2,241.35, a record high.

    Universal Health Services’ stock had been minding its business for most of the day–it was up 1.1% at $127.76 at 3:10 p.m. today–when the story by BuzzFeed’s Rosalind Adams went live. Here’s the gist:

    Millwood Hospital is part of Americas largest psychiatric hospital chain, Universal Health Services, or UHS. Its more than 200 psychiatric facilities across the country admitted nearly 450,000 patients last year. The result was almost $7.5 billion in revenues from inpatient care last year and profit margins of around 30%. More than a third of the companys overall revenue from both medical hospitals and psychiatric facilities comes from taxpayers through Medicare and Medicaid.

    A yearlong BuzzFeed News investigation based on interviews with 175 current and former UHS staff, including 18 executives who ran UHS hospitals; more than 120 additional interviews with patients, government investigators, and other experts; and a cache of internal documents raises grave questions about the extent to which those profits were achieved at the expense of patients.

    Universal Health Services market capitalization dropped to $10.7 billion today from $12.3 billion yesterday. It reported net income of $680 million on sales of $9 billion in 2015.

Best Low Price Stocks To Buy Right Now: St. Jude Medical, Inc.(STJ)

Advisors’ Opinion:

  • [By Emily Stewart]

    Paulson picked up 45,500 shares of St. Jude Medical (STJ) . The stake is worth $3.5 million as of the end of the second quarter.

    St. Jude Medical develops, manufactures and distributes cardiovascular medical devices for cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. It has a $23.6 billion market cap and trades at a P/E of 36.03. 

Hot Biotech Stocks To Watch Right Now

On Thursday, our Elite Opportunity Pronewsletter suggested getting into Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA: LABU) in part totake advantage of the January effect:

As a matter of fact, the entire biotech sector was the big performer yesterday, so we’re going to go ahead and take another shot with LABU, one of the primary bullish leveraged ETF’s tracking the biotech space. Many of you are fully aware of what happened the last two times we suggested LABU back in early November and then again in late November.

We clipped about 50% gains in a few short days the first time and ended up pretty much flat on the second attempt. However, if what we’re starting to see technically in biotech starts to pan out again, we could be looking at another nice trade. It just doesn’t come without a fair amount of risk, because LABU holds no prisoners when it decides to move the other way.

Hot Biotech Stocks To Watch Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Cory Renauer]

    Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS), saw a mix of setbacks and success in 2016.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) jumped as much as 14.5% today after announcing earnings after the bell yesterday. As a development-stage biotech, it wasn’t the revenue or the earnings that caused the spike, but the progression of Allnylam’s pipeline.

  • [By Chris Dier-Scalise]

    On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.

Hot Biotech Stocks To Watch Right Now: ARIAD Pharmaceuticals Inc.(ARIA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Healthcare shares gained around 0.73 percent in trading on Monday. Meanwhile, top gainers in the sector included Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and VCA Inc (NASDAQ: WOOF).

Hot Biotech Stocks To Watch Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Todd Campbell]

    A new and highly anticipated study byCelgene Corp. (NASDAQ:CELG) shows that its promising multiple sclerosis drug could soon reshape the $19 billion multiple sclerosis market. On Friday, management reported that ozanimod met its primary endpoint for reducing MS relapses better than Biogen Inc.’s (NASDAQ:BIIB) Avonex, and importantly, it did so without any new safety risks.

  • [By Brian Orelli]

    While that’s fine for clinical trials, it may make it difficult for Ionis’ drugs to compete with drugs that work as well but don’t have side effects that need to be monitored. Of course, for Spinraza, which Biogen (NASDAQ:BIIB) and Ionis recently got approved for spinal muscular atrophy, side effects aren’t an issue because there aren’t any other treatment options at the moment.

  • [By Ben Levisohn]

    Biogen (BIIB) tumbled to the bottom of the S&P 500 today after getting cut by two analysts.

    Agence France-Presse/Getty Images

    Biogen dropped 4.7% to $278.96 at 4:19 p.m. today, while the S&P 500 declined 0.2% to 2,381.38.

    Leerinks Geoffrey Porges cited the “slower than expected ramp for Spinraza” in cutting Biogen to Market Perform from Outperform, while Morgan Stanly’s Matthew Harrison wrote that his decision to cut Biogen to Market Weight from Overweight was “not a downside call, but a timing call.”

    Biogen’s market capitalization fell to $60.2 billion today from $63.2 billion yesterday. It reported net income of $3.7 billion on sales of $10.2 billion in 2016.

    Barron’s Teresa Rivas recommended buying Biogen in December after the company released positive trial data on its Alzheimer’s drug.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Thursday was Biogen Inc. (NASDAQ: BIIB) which traded down 4.6% at $279.08. The stocks 52-week range is $223.02 to $333.65. Volume was 3.4 million versus the daily average of 1.6 million shares.

Hot Biotech Stocks To Watch Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Paul Ausick]

    ArQule Inc. (NASDAQ: ARQL) dropped about 23% Friday, to post a new 52-week low of $1.13 after closing at $1.47 on Thursday. The stock’s 52-week high is $2.17. Volume was about 15 times the daily average of around 150,000 shares. The biopharmaceutical company said this morning that a phase 3 trial of a cancer drug did not meet the primary endpoint of improving overall survival.

Hot Biotech Stocks To Watch Right Now: Medivation Inc.(MDVN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Medivation Inc (NASDAQ: MDVN) got a boost, shooting up 24 percent to $46.35 amid word of a new report from Bloomberg, saying the company is working with bankers to defend itself against preliminary interest of a takeover. However, Reuters separately reported the company is working with JPMorgan to handle interest from other companies, but said Medivation has no interest in selling itself.

  • [By Monica Gerson]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Friday's regular session.

    PACCAR Inc (NASDAQ: PCAR) Aug16 52.5 Puts: 10000 @ ASK $1.70: 10k traded vs 335 OI: Earnings 7/26 $54.94 Ref
    Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Jul16 345 Puts: 949 @ ASK $8.70: 1003 traded vs 55 OI: Earnings 8/2 $360.20 Ref
    NVIDIA Corporation (NASDAQ: NVDA) Fri 6/24 47.0 Puts (Wkly) Sweep: 689 @ ASK $1.12: 3758 traded vs 136 OI: Earnings 8/4 $46.69 Ref
    Medivation Inc (NASDAQ: MDVN) Sep16 55.0 Puts: 4000 @ Above Ask! $3.40: 5303 traded vs 716 OI: Earnings 8/4 $59.44 Ref
    Expeditors International of Washington (NASDAQ: EXPD) Aug16 47.0 Puts Sweep: 950 @ ASK $1.35: 973 traded vs 381 OI: Earnings 8/2 $48.15 Ref

    Posted-In: Huge Put PurchasesNews Options Markets

  • [By Ben Levisohn]

    Macro considerations have continued to weigh on stocks whenever they’ve shown signs of life and consensus estimates for many of the large cap companies have been declining. With the sector’s underperformance, the delta in the average PEG ratio for biotech growth companies (excluding Medivation (MDVN)) compared to non-biotech growth companies is slightly wider than it’s been for most of the year. As such, we remain constructive on the sector. That said, while valuations are attractive on a relative basis, there remains some uncertainty for the group and we would not be surprised to see the volatility continue…

  • [By Scott Rubin]

    Big gainers on the day included Intersil Corp (NASDAQ: ISIL), which jumped 20 percent on news of a buyout, and Medivation (NASDAQ: MDVN), which added 20 percent on a deal with Pfizer (NYSE: PFE) related to its cancer drug. Cotiviti Holdings Inc (NYSE: COTV) lost around 9 percent in the wake of a mid-day sell-off and Marathon Oil Corporation (NYSE: MRO) fell 7 percent in the wake of a management shakeup.

  • [By Ben Levisohn]

    Well, it looks like Medivation (MDVN) now has five suitors after reports that Amgen (AMGN) is joining Pfizer (PFE), Sanofi (SNY), AstraZeneca (AZN) and Novartis (NVS) in considering a bid. Maxim’s Jason Kolbert and Jason McCarthy offer their thoughts:

    Medivation reports tonight at 4:30pm…

    We expect the focus to be on the recent proposals from Sanofi (SNY $38.75- NR); Pfizer (PFE $33.40 -NR), AstraZeneca (AZN $28.26-NR) and just today, Amgen (AMGN – $154.18 – NR)…

    Medivation is returning to new highs as suitors line up to make acquisition bids. In this scenario what is the right discount rate for modeling purposes?

    We believe our model for Xtandi revenues is good, therefore we review our risk rating and determine the following: 30% = $47 15% = $76 10% = $99

    With Medivation’s board having now said No to anything less than $65 per share, it suggests to us that the stability and predictability of Xtandi’s revenues is greater than we thought, the risk is lower. Our intermediate risk rating is 15% or $76 fair value.

    Shares of Medivation rose 0.3% to $59.22 today, while Pfizer gained 0.5% to $33.56, Sanofi fell 0.5% to $39.07, AstraZeneca dropped 0.6% to $39.07, Novartis declined 0.3% to $74.12, and Amgen ticked up 0.1% to $154.25.

     

  • [By Ben Levisohn]

    RBC’s Simos Simeonidis and Matthew Eckler try to find the right comparison for Pfizer’s (PFE) purchase of Medivation (MDVN):

    Scott Eisen/Bloomberg News

    We were obviously wrong with our Sector Perform rating: while we knew an M&A transaction was definitely a good possibility, we just could not get to this level of valuation using a realistic Xtandi model and thus could not recommend the stock. The only way for us to get to $81.50 (or even to $60-$70/share) would have been to assign very significant value to talazoparib. And we could not do that given the amount of available clinical evidence.Medivation shareholders who held on to their shares past the $50′s, did just that, were proven right and are now rewarded for it, since they believed that someone would be willing to pay for this asset just months ahead of Phase III data. The key question is why would a company be willing to part with what they claim/think may be a multibillion dollar drug that works in multiple cancers. We believe the obvious answer is because they’re smart and understand drug development risk better than most. We’ll know in a matter of months whether Pfizer/Medivation is like Amgen (AMGN)-Onyx (carfilzomib) or not.

Hot Biotech Stocks To Watch Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    Several big-name biotech companies step into the earnings confessional starting in the middle of the week, with Amgen, Inc. (NASDAQ: AMGN), Anthem Inc (NYSE: ANTM), and Celgene Corporation (NASDAQ: CELG) among the companies in play. That could bring opportunity with the  Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU) and the Direxion Daily S&P Biotech Bear 3X Shares (NYSE: LABD).

  • [By Stavros Georgiadis]

    Gilead Sciences (NSDQ:GILD) has underperformed the market with its stock price down almost 25% compared to a 10.33% gain in Nasdaq Composite (INDX:COMPX) and 14.60% gain of Dow Jones Industrial Average (INDX:INDU). Gilead and Amgen (NSDQ:AMGN)have had a very tough year, so it is interesting to know if now is the time to invest in GILD stock, not from a bottom fishing point of investing, which is often too risky, but on some solid financial and fundamentals arguments.

  • [By Ben Levisohn]

    Amgen (AMGN) has tumbled 3.6% to $158.65 after beating earnings forecasts but missing on sales.

    Buffalo Wild Wings (BWLD) has dropped 3% to $157.51 after its earnings fell short of the Street consensus.

  • [By Maxx Chatsko]

    Shares of Radius Health (NASDAQ:RDUS) rose over 20% Monday morning after Amgen (NASDAQ:AMGN) announced worrisome complications were discovered during a phase 3 trial for its osteoporosis drug candidate, Evenity. While the drug candidate met its primary endpoint in a more than 4,000-patient phase 3 study, a high rate of serious heart-related side effects were discovered. The drug was previously expected to gain marketing approval from the U.S. Food and Drug Administration in July, but that decision will now be delayed by up to a year or more, if the drug is approved at all.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest increase to 7.78 million shares from the previous level of 7.38 million. Shares closed most recently at $145.34, in a 52-week trading range of $133.64 to $176.85.

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) tumbled to the bottom of the S&P 500 today after a judge said the company could be forced to stop selling an anti-cholesterol drug due to violating an Amgen (AMGN) patent.